Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21236343 | 0.84 | CYP1A2 (0.37) | UCHL1SNCADGAT1CYP1A2EGFR | |
| SCHEMBL29421542 | 0.84 | CYP1A2 (0.37) | UCHL1SNCADGAT1CYP1A2EGFR | |
| SCHEMBL24155618 | 0.83 | LIPE (0.38) | ALPLDGAT1CYP1A2 | |
| SCHEMBL854982 | 0.83 | NUDT1 (0.35) | ALPLUCHL1CYP1A2METAP2 | |
| SCHEMBL14726790 | 0.83 | UCHL1 (0.34) | UCHL1DGAT1 | |
| SCHEMBL2066865 | 0.80 | ALPL (0.34) | ALPLUCHL1DGAT1EGFR | |
| SCHEMBL15535603 | 0.80 | ALPL (0.34) | ALPLUCHL1 | |
| SCHEMBL16076005 | 0.80 | ALPL (0.32) | ALPLUCHL1 | |
| SCHEMBL2066860 | 0.79 | UCHL1 (0.32) | ALPLUCHL1DGAT1 | |
| SCHEMBL30606415 | 0.79 | NR1H2 (0.38) | UCHL1DGAT1CYP1A2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | claimed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | claimed |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4212524-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | Betta Pharmaceuticals Co., Ltd (CN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116134029-A | Oxo-nitrogen ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114790197-A | CD73 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022121914-A1 | OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121914-A1 | OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022052886-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-7122694-B2 | Hydroboronation process | BORON MOLECULAR PTY LIMITED (AU) | 2006-10-17 | — | — | US | disclosed |
| EP-1127060-B8 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | disclosed |
| EP-1127060-B1 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2004-04-07 | — | — | EP | disclosed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | disclosed |
| EP-1127060-A4 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | ALPL 737/4885QPCT 417/4885QPCTL 866/4885 |
| US-20040133028-A1 | Hydroboronation process | ALKBH3, HPD, HVCN1 | ALPL 4836/4885QPCT 1024/4885QPCTL 3077/4885 |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | ENTPD5, ENTPD1, NT5E | ALPL 665/4885QPCT 1760/4885QPCTL 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.